This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, July 8, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Tuesday, July 9
th at 9:30 a.m. Eastern Time at the JMP Securities Healthcare Conference at the St. Regis Hotel in New York.
A live webcast will be available through the Investor Relations page of the Trius website at
http://investor.triusrx.com/events.cfm . A webcast replay will be available approximately two hours after the presentation and will be archived for 30 days.
About Trius Therapeutics
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious gram-positive infections, including those caused by methicillin-resistant
Staphylococcus aureus (MRSA). Trius has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company's tedizolid phosphate clinical program, Trius has initiated Investigational New Drug (IND) enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of
Pseudomonas. For more information, visit
CONTACT: Public Relations Contact:
Laura Kempke/Stacey Holifield at MSLGROUP
Investor Relations Contact:
Stefan Loren at Westwicke Partners, LLC